Eliglustat: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AOTMIT (Poland), CIPM (Spain) and G-BA (Germany), among others, recommended or restricted eliglustat, while TLV (Sweden) did not recommend it.
Where eliglustat met resistance it was usually narrowed rather than refused: 4 of 10 decisive outcomes were recommendations with restrictions, against 2 outright refusals.
Assessment has run over 10.3 years, from 20 May 2015 at AWMSG (Wales) to 24 Sep 2025 at CIPM (Spain).
Every one of the eight highest-volume agencies in this archive has a record for eliglustat.
The file is active: 3 of 12 records date from 2023 or later.
3 distinct indication wordings are recorded for eliglustat by the agencies that label one in English (AWMSG, PBAC and SMC).
1 of these 12 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess eliglustat, on 20 May 2015; CIPM (Spain) did not open a file until 24 Sep 2025 — an unusually long tail of 10.3 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 7 years in total.
Restriction is doing real work here: 4 of 10 decisive outcomes narrowed eliglustat to a subgroup rather than accepting or refusing it outright, at AOTMIT (Poland), G-BA (Germany) and ZIN (Netherlands).
2 of the 10 agencies here assessed eliglustat more than once, G-BA (Germany) most often at 2 entries — repeat review is the norm for this molecule rather than the exception.
10 of the 18 agencies in this archive hold a record for eliglustat.
The full ledger for eliglustat reads 4 recommended, 4 restricted, 2 not recommended and 1 superseded, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CIPM (Spain) | 24 Sep 2025 | Indicaciones terapéuticas autorizadas: Tratamiento a largo plazo de pacientes adultos con enfermedad de Gaucher de tipo … | financed by the SNS · art. 92 a, c | source |
| G-BA (Germany) | 18 Jun 2025 | Cerdelga — benefit assessment §35a | added benefit: non-quantifiable (hint) | source |
| PHARMAC (New Zealand) | 6 Nov 2024 | type 1 or type 3 Gaucher disease | PTAC advice: Cost Neutral | source |
| TLV (Sweden) | 28 Oct 2019 | Cerdelga ingår inte i högkostnadsskyddet | rejection or exclusion | source |
| AOTMIT (Poland) | 3 Oct 2018 | Cerdelga reimbursement recommendation | recommended conditionally | source |
7 further decisions for eliglustat, across 7 agencies, are not shown here. They link to 7 further source documents.
Related molecules
- teduglutide — same ATC class A16A — Other alimentary tract and metabolism
- sapropterin — same ATC class A16A — Other alimentary tract and metabolism
- miglustat — same ATC class A16A — Other alimentary tract and metabolism
- migalastat — same ATC class A16A — Other alimentary tract and metabolism
- cerliponase alfa — same ATC class A16A — Other alimentary tract and metabolism
- givosiran — same ATC class A16A — Other alimentary tract and metabolism
Coverage: 12 decisions for eliglustat from 10 agencies, 2015 to 2025. Data to 7 Sep 2026. ATC class A16A — Other alimentary tract and metabolism. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.